ValiRx - VAL301 update
VAL Thu, 04 Jul 2019, 09:00am BST
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Victoria D'Aquino, Research & Development Officer at ValiRx, the clinical stage biotechnology company, provides an update on VAL301. This is following the announcement that the Company’s clinical team has signed an agreement to work with Aptus Clinical Ltd, the UK based, clinical Contract Research Organisation, to effectuate a clinical development plan for VAL301 incorporating a Phase I/II study design concept in Endometriosis.